TY - JOUR
T1 - New 2030 Global Targets for Histoplasmosis from International Society for Human and Animal Mycology (ISHAM) 2025 Histoplasmosis Working Group
AU - Pasqualotto, Alessandro C
AU - Denning, David W
AU - Govender, Nelesh P
AU - Hagen, Ferry
AU - Zancope-Oliveira, Rosely M
AU - Caceres, Diego H
AU - Francoise, Ugo
AU - Guimaraes, Allan
AU - Damasceno, Lisandra S
AU - Falci, Diego R
AU - Gomez, Beatriz L
AU - Schwartz, Ilan
AU - Vidal, Jose E
AU - Galan, Luis E
AU - Xavier, Melissa O
AU - Nacher, Mathieu
AU - Effron, Guillermo G
AU - Brown, Gordon
AU - Barros, Nicolas
AU - Godoy, Cassia M
AU - Fraga, Taiguara
AU - Soares, Renata B A
AU - Severo, Cecilia B
AU - Schwarzbold, Alexandre V
AU - Berrio, Indira
AU - de Melo, Marineide G
AU - Reis, Nicole
AU - Tenorio, Bernardo G
AU - Leitao, Terezinha M J
AU - Bastos, Claudilson J de C
AU - Bay, Monica B
AU - de Lacerda, Marcus V G
AU - Bazana, Luana C G
AU - Lana, Daiane F Dalla
AU - Vieceli, Tarsila
AU - Riche, Cezar V W
AU - Arathoon, Eduardo
AU - Canteros, Cristina
AU - Boulware, David
AU - Alastruey-Izquierdo, Ana
AU - Oladele, Rita
AU - Teixeira, Marcus de M
AU - Colombo, Arnaldo L
AU - Perez, Freddy M
AU - Chiller, Tom
AU - Bahr, Nathan C
AU - Tudela, Juan L R
AU - Adenis, Antoine
N1 - Publisher Copyright:
© 2026, Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2026/3
Y1 - 2026/3
N2 - Histoplasmosis remains a neglected yet deadly fungal infection, disproportionately affecting persons living with HIV/AIDS and other immunocompromised populations in endemic regions. Despite the World Health Organization's designation of Histoplasma as a high-priority pathogen, the disease remains underdiagnosed and excluded from national surveillance systems, resulting in delayed treatment and high death rates. To coordinate a global response, the International Society for Human and Animal Mycology convened a Histoplasmosis Working Group during its 2025 congress in Brazil. Experts engaged in structured discussions across 5 domains: awareness, research, diagnostics and treatment, capacity building, and fungal biology. The group highlighted persistent diagnostic delays, underuse of antigen testing, and poor access to liposomal amphotericin B and itraconazole. Innovations such as lateral flow assays and molecular tools were discussed, alongside the need for biobanks and validated diagnostic algorithms. A global 90-90-90 target for histoplasmosis by 2030 was proposed to improve diagnosis, treatment, and survival.
AB - Histoplasmosis remains a neglected yet deadly fungal infection, disproportionately affecting persons living with HIV/AIDS and other immunocompromised populations in endemic regions. Despite the World Health Organization's designation of Histoplasma as a high-priority pathogen, the disease remains underdiagnosed and excluded from national surveillance systems, resulting in delayed treatment and high death rates. To coordinate a global response, the International Society for Human and Animal Mycology convened a Histoplasmosis Working Group during its 2025 congress in Brazil. Experts engaged in structured discussions across 5 domains: awareness, research, diagnostics and treatment, capacity building, and fungal biology. The group highlighted persistent diagnostic delays, underuse of antigen testing, and poor access to liposomal amphotericin B and itraconazole. Innovations such as lateral flow assays and molecular tools were discussed, alongside the need for biobanks and validated diagnostic algorithms. A global 90-90-90 target for histoplasmosis by 2030 was proposed to improve diagnosis, treatment, and survival.
KW - Animals
KW - Antifungal Agents/therapeutic use
KW - Global Health
KW - Histoplasma
KW - Histoplasmosis/diagnosis
KW - Humans
U2 - 10.3201/eid3203.251165
DO - 10.3201/eid3203.251165
M3 - Article
C2 - 41863768
SN - 1080-6040
VL - 32
SP - 1
EP - 9
JO - Emerging infectious diseases
JF - Emerging infectious diseases
IS - 3
ER -